CN112535720A - Application of Wangshi Baochi pill in preparation of medicine for preventing and treating intestinal injury - Google Patents
Application of Wangshi Baochi pill in preparation of medicine for preventing and treating intestinal injury Download PDFInfo
- Publication number
- CN112535720A CN112535720A CN201910898075.9A CN201910898075A CN112535720A CN 112535720 A CN112535720 A CN 112535720A CN 201910898075 A CN201910898075 A CN 201910898075A CN 112535720 A CN112535720 A CN 112535720A
- Authority
- CN
- China
- Prior art keywords
- pill
- preventing
- medicine
- intestinal
- intestinal injury
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003814 drug Substances 0.000 title claims abstract description 40
- 239000006187 pill Substances 0.000 title claims abstract description 30
- 208000037817 intestinal injury Diseases 0.000 title claims abstract description 28
- 229940079593 drug Drugs 0.000 claims description 15
- 210000001035 gastrointestinal tract Anatomy 0.000 claims description 10
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 claims description 2
- 229960001138 acetylsalicylic acid Drugs 0.000 claims description 2
- 239000002246 antineoplastic agent Substances 0.000 claims description 2
- 229940044683 chemotherapy drug Drugs 0.000 claims description 2
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 claims description 2
- QYSPLQLAKJAUJT-UHFFFAOYSA-N piroxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=CC=CC=N1 QYSPLQLAKJAUJT-UHFFFAOYSA-N 0.000 claims description 2
- 229960002702 piroxicam Drugs 0.000 claims description 2
- 230000002265 prevention Effects 0.000 claims 2
- 230000000266 injurious effect Effects 0.000 claims 1
- 241000699670 Mus sp. Species 0.000 description 24
- 230000000694 effects Effects 0.000 description 13
- 230000037396 body weight Effects 0.000 description 12
- 230000001154 acute effect Effects 0.000 description 10
- 230000000968 intestinal effect Effects 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 5
- KXGCNMMJRFDFNR-WDRJZQOASA-N linaclotide Chemical compound C([C@H](NC(=O)[C@@H]1CSSC[C@H]2C(=O)N[C@H]3CSSC[C@H](N)C(=O)N[C@H](C(N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N2)=O)CSSC[C@H](NC(=O)[C@H](C)NC(=O)[C@@H]2CCCN2C(=O)[C@H](CC(N)=O)NC3=O)C(=O)N[C@H](C(NCC(=O)N1)=O)[C@H](O)C)C(O)=O)C1=CC=C(O)C=C1 KXGCNMMJRFDFNR-WDRJZQOASA-N 0.000 description 5
- 229960000812 linaclotide Drugs 0.000 description 5
- 108010024409 linaclotide Proteins 0.000 description 5
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 230000003870 intestinal permeability Effects 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 239000002504 physiological saline solution Substances 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 230000002354 daily effect Effects 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 229920002307 Dextran Polymers 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 210000002249 digestive system Anatomy 0.000 description 2
- 208000010643 digestive system disease Diseases 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 238000001647 drug administration Methods 0.000 description 2
- 230000005284 excitation Effects 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- RDOIQAHITMMDAJ-UHFFFAOYSA-N loperamide Chemical compound C=1C=CC=CC=1C(C=1C=CC=CC=1)(C(=O)N(C)C)CCN(CC1)CCC1(O)C1=CC=C(Cl)C=C1 RDOIQAHITMMDAJ-UHFFFAOYSA-N 0.000 description 2
- 229960001571 loperamide Drugs 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 230000035515 penetration Effects 0.000 description 2
- 238000010926 purge Methods 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 244000247747 Coptis groenlandica Species 0.000 description 1
- 235000002991 Coptis groenlandica Nutrition 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 244000248416 Fagopyrum cymosum Species 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010062717 Increased upper airway secretion Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 244000299790 Rheum rhabarbarum Species 0.000 description 1
- 235000009411 Rheum rhabarbarum Nutrition 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000000973 chemotherapeutic effect Effects 0.000 description 1
- 208000021735 chronic enteritis Diseases 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 210000004347 intestinal mucosa Anatomy 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 208000026435 phlegm Diseases 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 231100000701 toxic element Toxicity 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/70—Polygonaceae (Buckwheat family), e.g. spineflower or dock
- A61K36/708—Rheum (rhubarb)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/28—Mercury; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/47—Euphorbiaceae (Spurge family), e.g. Ricinus (castorbean)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/71—Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal
- A61K36/718—Coptis (goldthread)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/888—Araceae (Arum family), e.g. caladium, calla lily or skunk cabbage
- A61K36/8884—Arisaema, e.g. Jack in the pulpit
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/89—Cyperaceae (Sedge family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
- A61K36/8966—Fritillaria, e.g. checker lily or mission bells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/906—Zingiberaceae (Ginger family)
- A61K36/9068—Zingiber, e.g. garden ginger
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Inorganic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
The invention provides application of Wangshi Baochi pills in preparation of a medicine for preventing and treating intestinal injury.
Description
Technical Field
The invention relates to the field of treatment of digestive system diseases, in particular to application of Wangshi Baochi pills in preparation of a medicine for preventing and treating intestinal injury.
Background
When some clinical medicines, such as non-steroidal anti-inflammatory drugs, chemotherapeutic drugs and the like are used, the medicines have side effects on gastrointestinal tracts, so that intestinal tracts are damaged, the permeability of intestinal mucosa to macromolecular substances, antigens and toxic elements is increased, and the substances enter blood to generate symptoms such as allergy, inflammation and the like. The Wang Shi Bao Chi Wan (WSBCW) is a small pill prepared from coptis root, rhubarb and other medicinal ingredients through processing, has the effects of clearing heat and purging fire, purging stagnation, removing phlegm and relieving asthma and the like, is widely used for treating diseases of digestive systems and respiratory systems of children due to exact curative effect, and is also used for treating the diseases of the digestive systems of adults in recent years.
Chinese patent document CN104771453A discloses the application of a combination of a wild buckwheat rhizome preparation and a Wangshi Baochi pill in preparing a medicine for treating chronic enteritis. Chinese patent document CN104645299A discloses the application of Wangshi Baochi pill in preparing external medicine for treating digestive system diseases, and better treatment effect is achieved by the disappearance of symptoms of Wangshi Baochi pill, diarrhea and the like. However, at present, there is no report about the application of Wangshi Baochi pill in preventing and treating intestinal injury.
Disclosure of Invention
Therefore, the invention aims to provide the application of the Wangshi Baochi pill in preparing the medicine for preventing and treating intestinal injury.
Therefore, the invention provides the application of the Wangshi Baochi pill in preparing the medicine for preventing and treating the intestinal injury.
The Wangshi Baochi pill can be used for preparing a medicine for preventing and treating intestinal injury, and the Wangshi Baochi pill can be used for preventing and treating the intestinal injury by reducing intestinal penetration.
The Wangshi Baochi pill is used for preparing a medicine for preventing and treating intestinal injury, wherein the Wangshi Baochi pill accounts for 100% of the weight of the medicine.
The Wangshi Baochi pill is used for preparing a medicine for preventing and treating intestinal injury, wherein the intestinal injury is caused by one or more of nonsteroidal anti-inflammatory medicines or chemotherapeutic medicines which have an injury effect on the intestinal tract.
The Wangshi Baochi pill is used for preparing a medicine for preventing and treating intestinal injury, wherein the intestinal injury is caused by one or two of aspirin and piroxicam.
The Wangshi Baochi pill is used for preparing a medicine for preventing and treating intestinal injury, and the medicine is non-acute administration in the process of preventing and treating the intestinal injury.
The Wangshi Baochi pill is used for preparing a medicine for preventing and treating intestinal injury, and is administrated for more than 2 days, preferably for 2 days to 2 weeks in the process of preventing and treating the intestinal injury.
The technical scheme of the invention has the following advantages:
1. according to the application of the Wangshi Baochi pill in preparing the medicine for preventing and treating the intestinal injury, researches show that the Wangshi Baochi pill can obviously reduce intestinal permeation so as to protect the intestinal tract, and the Wangshi Baochi pill is used for preparing the medicine so as to ensure that the medicine has the effect of protecting the intestinal tract and can be used for preventing and treating diseases related to the intestinal injury.
2. The Wangshi Baochi pill can obviously reduce intestinal permeation, and is used for preparing medicines, so that the medicines have the effect of protecting the intestinal tract, and can be used for preventing and treating diseases related to the intestinal tract injury caused by clinical medicines with side effects on the intestinal tract.
3. The invention provides application of Wangshi Baochi pills in preparation of a medicine for preventing and treating intestinal injury, wherein the medicine is subjected to non-acute administration in the process of preventing and treating the intestinal injury, and researches show that the medicine is subjected to pre-administration for a period of time, has a more obvious effect of reducing intestinal permeation and stronger effect of protecting the integrity of intestinal tracts compared with acute one-time administration, and can achieve a better effect of preventing and treating the intestinal injury through continuous non-acute administration.
Drawings
In order to more clearly illustrate the embodiments of the present invention or the technical solutions in the prior art, the drawings used in the description of the embodiments or the prior art will be briefly described below, and it is obvious that the drawings in the following description are some embodiments of the present invention, and other drawings can be obtained by those skilled in the art without creative efforts.
FIG. 1 is a graph showing the results of experiments on the effect of Wang Shi Baochi pill on intestinal permeability in the case of non-acute administration with pre-drug intervention in the experimental examples of the present invention;
FIG. 2 is a graph showing the results of experiments on the effect of Wang Shi Baochi pill on intestinal permeability in the case of acute administration without prior intervention of drugs in the experimental examples of the present invention.
Detailed Description
Example 1
The embodiment provides a Wang Shi Bao Chi Wan, and the specific composition and the usage amount of the Wang Shi Bao Chi Wan refer to the instruction of the Wang Shi Bao Chi Wan produced by essence pharmaceutical group GmbH.
Examples of the experiments
Experiment on influence of Wangshi Baochi pill (WSBCW) on intestinal permeability
1. Experiment grouping
Female mice of six to eight weeks old are selected and randomly divided into six groups (ten mice in each group), and the specific grouping conditions are as follows: group 1: blank control group; group 2: intestinal transit down-regulated control group (cloperamide-treated group); group 3: intestinal transit up-regulated control group (linaclotide-treated group); group 4: WSBCW 40mg/kg body weight treatment group; group 5: WSBCW 120mg/kg body weight treatment group; group 6: WSBCW 360mg/kg body weight treatment group.
2. Barrier penetration test
2.1 non-acute administration with Pre-drug intervention
Carrying out early drug intervention on the mice in the groups 1-6, specifically, carrying out intragastric administration on the mice in the groups 1-3 by using physiological saline every day; group 4 mice were gavaged daily with 40mg/kg body weight of WSBCW; mice in group 5 were gavaged daily with WSBCW at 120mg/kg body weight; mice in group 6 were gavaged daily with WSBCW at 360mg/kg body weight for 2 weeks. Then, the administration treatment is carried out, and the specific administration operation is as follows: the group 1 mice were gavaged with physiological saline, the group 2 mice were gavaged with cloperamide (Loperamide), the group 3 mice were gavaged with Linaclotide (Linaclotide), the group 4 mice were gavaged with WSBCW at 40mg/kg body weight, the group 5 mice were gavaged with WSBCW at 120mg/kg body weight; group 6 mice were gavaged with WSBCW at 360mg/kg body weight. The intragastric administration is carried out by adopting a suspension of dissolved medicines and physiological saline. After the administration, six groups of mice were fasted for one night, then filled with 100 μ l of 100mg/ml FITC-Dextran, and after 90 minutes of gastric lavage, the mandibular venous blood of the mice was taken, after dilution, the fluorescence intensity in serum was measured, and the excitation wavelength was 485nm and the emission wavelength was 535 nm. The assay results obtained are shown in figure 1, where P < 0.05.
2.2 acute administration without Pre-drug intervention
The method is characterized in that the 1-6 groups of mice are not subjected to early drug intervention, and the drug administration treatment is directly carried out, wherein the specific drug administration operation comprises the following steps: the group 1 mice were gavaged with physiological saline, the group 2 mice were gavaged with cloperamide (Loperamide), the group 3 mice were gavaged with Linaclotide (Linaclotide), the group 4 mice were gavaged with WSBCW at 40mg/kg body weight, the group 5 mice were gavaged with WSBCW at 120mg/kg body weight; group 6 mice were gavaged with WSBCW at 360mg/kg body weight. The intragastric administration is carried out by adopting a suspension of a medicine dissolved in normal saline. After the administration, six groups of mice were fasted for one night, then filled with 100 μ l of 100mg/ml FITC-Dextran, and after 90 minutes of gastric lavage, the mandibular venous blood of the mice was taken, after dilution, the fluorescence intensity in serum was measured, and the excitation wavelength was 485nm and the emission wavelength was 535 nm. The results are shown in fig. 2, wherein P <0.05 and P < 0.01.
The reduction of intestinal permeability by WSBCW is more pronounced with non-acute dosing regimens with prior intervention than with acute dosing regimens without prior intervention.
It should be understood that the above examples are only for clarity of illustration and are not intended to limit the embodiments. Other variations and modifications will be apparent to persons skilled in the art in light of the above description. And are neither required nor exhaustive of all embodiments. And obvious variations or modifications therefrom are within the scope of the invention.
Claims (3)
1. An application of Wangshi Baochi pill in preparing the medicines for preventing and treating intestinal injury is disclosed.
2. Use of Wangshi Baochi pill in the preparation of a medicament for the prevention and treatment of intestinal injury according to claim 1, wherein the intestinal injury is caused by one or more of non-steroidal anti-inflammatory drugs or chemotherapeutic drugs having an injurious effect on the intestinal tract.
3. Use of Wangshi Baochi pill in the preparation of a medicament for the prevention and treatment of intestinal injury according to claim 1 or 2, characterized in that the intestinal injury is caused by one or both of aspirin or piroxicam.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910898075.9A CN112535720A (en) | 2019-09-23 | 2019-09-23 | Application of Wangshi Baochi pill in preparation of medicine for preventing and treating intestinal injury |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910898075.9A CN112535720A (en) | 2019-09-23 | 2019-09-23 | Application of Wangshi Baochi pill in preparation of medicine for preventing and treating intestinal injury |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN112535720A true CN112535720A (en) | 2021-03-23 |
Family
ID=75012814
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201910898075.9A Pending CN112535720A (en) | 2019-09-23 | 2019-09-23 | Application of Wangshi Baochi pill in preparation of medicine for preventing and treating intestinal injury |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN112535720A (en) |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103919982A (en) * | 2014-04-22 | 2014-07-16 | 精华制药集团股份有限公司 | Application of Wangshi Baochi pills in preparation of drug for treating gastrointestinal type cold |
| CN104645299A (en) * | 2015-03-11 | 2015-05-27 | 精华制药集团股份有限公司 | Application of Wangshi safeguarding red pills in preparation of externally-applied medicines for treating digestive system diseases |
| CN104771453A (en) * | 2015-03-12 | 2015-07-15 | 精华制药集团股份有限公司 | Application of preparation composed of wild buckwheat preparation and Wangshi Baochi pill in preparation of drugs for treating chronic enteritis |
| CN106511951A (en) * | 2016-12-26 | 2017-03-22 | 精华制药集团股份有限公司 | Application of milk of lactating woman taking Wangshi Baochi pills in treating infant diseases |
-
2019
- 2019-09-23 CN CN201910898075.9A patent/CN112535720A/en active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103919982A (en) * | 2014-04-22 | 2014-07-16 | 精华制药集团股份有限公司 | Application of Wangshi Baochi pills in preparation of drug for treating gastrointestinal type cold |
| CN104645299A (en) * | 2015-03-11 | 2015-05-27 | 精华制药集团股份有限公司 | Application of Wangshi safeguarding red pills in preparation of externally-applied medicines for treating digestive system diseases |
| CN104771453A (en) * | 2015-03-12 | 2015-07-15 | 精华制药集团股份有限公司 | Application of preparation composed of wild buckwheat preparation and Wangshi Baochi pill in preparation of drugs for treating chronic enteritis |
| CN106511951A (en) * | 2016-12-26 | 2017-03-22 | 精华制药集团股份有限公司 | Application of milk of lactating woman taking Wangshi Baochi pills in treating infant diseases |
Non-Patent Citations (2)
| Title |
|---|
| 于康等: "《临床营养治疗学》", 31 May 2004, 中国协和医科大学出版社 * |
| 李建婷等: "王氏保赤丸对抗生素诱导肠道菌群失调小鼠肠道保护作用及肝脏毒性的影响研究", 《吉林医学》 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2445870T3 (en) | Marine antiallergic biopolymers | |
| US20120309715A1 (en) | Use of Simethicone in Constipated Patients | |
| Obidike et al. | Microencapsulation enhances the anti-ulcerogenic properties of Entada africana leaf extract | |
| US7867523B2 (en) | Pharmaceutical composition | |
| CN116600794A (en) | Chenopodin compositions and methods for the treatment and prevention of covd-19 and related pathologies | |
| Aryan et al. | Evaluation of the efficacy of oral nano‐silymarin formulation in hospitalized patients with COVID‐19: A double‐blind placebo‐controlled clinical trial | |
| US4642232A (en) | Formulated allergen preparation and its use | |
| Mahboubi | Aloe Vera (Aloe barbadensis) gel for the management of gastroesophageal reflux disease (GERD) | |
| CN112535720A (en) | Application of Wangshi Baochi pill in preparation of medicine for preventing and treating intestinal injury | |
| ITMI20121317A1 (en) | COMPOSITIONS FOR THE TREATMENT OF ONCOLOGICAL FATIGUE | |
| CN106266023B (en) | Medicine for treating gastric ulcer and preparation method thereof | |
| CN101926896A (en) | Traditional Chinese medicine preparation for treating gout and preparation method thereof | |
| CN101152196A (en) | Application of Panax notoginseng saponins and its monomers in the preparation of drugs for treating depression | |
| CN105687534B (en) | A kind of traditional Chinese medicine composition and application thereof for preventing or treating rhinitis | |
| US20170020946A1 (en) | Analgesic compositions and methods of use | |
| US20230061908A1 (en) | Vsv (vitamin c-spirulina-vitamin d) composition, kit and method | |
| Kumar et al. | Herbal Bioactives for the Treatment of Gastrointestinal Tract Disorders | |
| CN101045127A (en) | Medications and/or Food Supplements Containing Nisylen, Onion, Eyebright, Belladonna, and/or Diluted Mercury | |
| ES2809463T3 (en) | Composition of natural anti-flu antioxidants | |
| Zhou et al. | Therapeutic effects of the combination of traditional Chinese medicine and western medicine on patients with peptic ulcers | |
| Kozyreva et al. | Clinical evaluation of the effectiveness of the combined use of phytotherapy and sulfide mineral waters to optimize the basic treatment of chronic gingivitis | |
| CN115916204A (en) | Methods for treating RNA viral infections including COVID-19 (SARS-CoV-2) | |
| CN102936282A (en) | Gall-stone removing compound and application thereof | |
| Villa et al. | Preclinical and clinical status of nanocarriers for colon targeting | |
| Koshta et al. | Herbal Formulations Used for Treatment/Management of Cancer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20210323 |